Jefferies initiated coverage of Keros Therapeutics (KROS) with a Buy rating and $107 price target The firm says Keros has expertise in the TGF-beta pathway, which plays roles in blood, lung and muscle disorders. With experience in approved TGF-beta drugs Reblozyl and Winrevair, the company is developing drugs optimized for better efficacy and safety, the analyst tells investors in a research note. Jefferies believes a “slice of share” could drive $2B-plus peak sales for Keros or a $6B-plus valuation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KROS:
- Keros Therapeutics initiated with a Buy at Jefferies
- Keros Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Disney initiated, Cisco upgraded: Wall Street’s top analyst calls
- Keros Therapeutics Appoints New Chief Medical Officer
- Keros Therapeutics appoints Chyung as CMO
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
